Kancera develops drugs that counteract damage from acute and chronic inflammation.

Fraktalkine blocker KAND567 is developed primarily to effectively counteract hyperinflammation in various medical conditions and thus protect vital organs, e.g. in connection with heart attacks and severe viral infections.